ATAGI statement on the clinical use of Arexvy (RSV PRE-F3) vaccine for RSV

This clinical statement from the Australian Technical Advisory Group on Immunisation (ATAGI) provides advice on the use of the Arexvy vaccine for the prevention of respiratory syncytial virus (RSV) disease in older adults in Australia.

Downloads

ATAGI statement on the clinical use of Arexvy (RSV PRE-F3) vaccine for RSV

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication date:
Date last updated:
Publication type:
Fact sheet
Audience:
Health sector
Language:
English
Description:

ATAGI has provided clinical advice on the use of the Arexvy (RSV PRE-F3) vaccine currently available on the private market in Australia to prevent illness and severe complications associated with respiratory syncytial virus infection.

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.